- FDA committee recommends approval of OraSure's in-home HIV test
- FDA to review Achillion's HCV drug on fast track basis
- FDA unclear on link between Novartis' MS drug Gilenya, patient deaths
- Stiefel's Fabior foam approved for treating acne
- Ohr Pharmaceutical wins fast track designation for wet AMD product candidate
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Avedro's VibeX granted orphan drug status as treatment for corneal ectasia following refractive surgery
Monday, December 19 2011 | Comments
What's This?
The Food and Drug Administration granted Avedro Inc.'s VibeX (riboflavin) ophthalmic solution an orphan drug designation for use in combination with Avedro's KXL system for corneal crosslinking to treat corneal ectasia following refractive surgery, such as LASIK and photorefractive keratectomy.Avedro's KXL crosslinking procedure involves the topical application of VibeX to the cornea after epithelium removal. Ultraviolet light from the KXL system is applied to the eye, which activates the VibeX in the stroma, resulting in cornea strengthening.
Corneal ectasia is a rare outcome of refractive surgery but is a difficult-to-manage, progressive condition for which there is no currently approved therapy, Avedro noted.
This is the second orphan drug designation for VibeX. The ophthalmic solution also received orphan drug status in September for the treatment of keratoconus.
Avedro expects to file for FDA approval of VibeX in the first quarter of next year. If VibeX is approved, Avedro will have exclusive marketing rights to the product in the United States.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- Allergan's Trivaris injections may slow diabetic retinopathy, though laser therapy remains treatment of choice, investigators conclude
- Baerveldt 250-mm2 glaucoma device appears more effective at lowering IOP than is Ahmed implant, retrospective study reveals
- NHANES data show increased prevalence of vision loss, impairment among adults with diabetes
- White-coat hypertension not benign for patients with type 2 diabetes, study suggests
- Adalimumab reduces incidence of uveitis flares in patients with AS, study data show
- Diabetes glucose cutoff not useful for detecting retinopathy
- ThromboGenics seeks FDA approval of treatment for eye disorder
- ThromboGenics reports FDA likely to grant ocriplasmin BLA priority review status
- Ranibizumab improves vision-related function in neovascular AMD
- Ampio ends midstage trial of Optina in DME early following positive interim review; shares rise
